These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 3582088)
41. Hypoglycemic coma associated with subcutaneous insulin infusion by portable pump. Lock DR; Rigg LA Diabetes Care; 1981; 4(3):389-91. PubMed ID: 7047116 [TBL] [Abstract][Full Text] [Related]
42. [Intensive insulin therapy by multiple sub-cutaneous injections or CSII: indications and role of diabetic patient education]. Sonnenberg GE; Jörgens V; Spraul M; Chantelau EA; Berger M Journ Annu Diabetol Hotel Dieu; 1985; ():75-86. PubMed ID: 2577979 [No Abstract] [Full Text] [Related]
43. CSII and ICT in treating Type I diabetic individuals. Georgopoulos A Diabetes Care; 1983; 6(2):201-1. PubMed ID: 6343026 [No Abstract] [Full Text] [Related]
44. Perceptions and experiences of adult patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: Results of an online survey. Taleb N; Messier V; Ott-Braschi S; Ardilouze JL; Rabasa-Lhoret R Diabetes Res Clin Pract; 2018 Oct; 144():42-50. PubMed ID: 30077691 [TBL] [Abstract][Full Text] [Related]
45. Observations on blood lipid and intermediary metabolite concentrations during conventional insulin treatment or CSII. Lawson P; Home PD; Bergenstal R Diabetes; 1985 Aug; 34 Suppl 3():27-30. PubMed ID: 3894126 [TBL] [Abstract][Full Text] [Related]
46. Basal rates and circadian profiles in continuous subcutaneous insulin infusion (CSII) differ for preschool children, prepubertal children, adolescents and young adults. Bachran R; Beyer P; Klinkert C; Heidtmann B; Rosenbauer J; Holl RW; ; ; Pediatr Diabetes; 2012 Feb; 13(1):1-5. PubMed ID: 21545675 [TBL] [Abstract][Full Text] [Related]
47. Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps. Potti LG; Haines ST J Am Pharm Assoc (2003); 2009; 49(1):e1-13; quiz e14-7. PubMed ID: 19196588 [TBL] [Abstract][Full Text] [Related]
48. Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study. Renard E; Guerci B; Leguerrier AM; Boizel R; Diabetes Technol Ther; 2010 Oct; 12(10):769-73. PubMed ID: 20809682 [TBL] [Abstract][Full Text] [Related]
51. [Pumps for insulin infusion in the ambulatory treatment of diabetes mellitus]. Mirouze J Presse Med; 1987 Oct; 16(32):1585-90. PubMed ID: 2958834 [TBL] [Abstract][Full Text] [Related]
52. A case of congenital generalized lipodystrophy with lipoatrophic diabetes developing anti-insulin antibodies. Usui H; Makino H; Shikata K; Sugimoto T; Wada J; Yamana J; Matsuda M; Yoneda M; Koshima I Diabet Med; 2002 Sep; 19(9):794-5. PubMed ID: 12207821 [No Abstract] [Full Text] [Related]
53. The effect of continuous subcutaneous insulin infusion on endogenous insulin secretion in type I diabetes. Pietri A; Alford M; Raskin P Diabetes Care; 1982; 5(3):330-3. PubMed ID: 6756842 [TBL] [Abstract][Full Text] [Related]
54. Feasibility of continuous subcutaneous insulin infusion and daily supplemental insulin glargine injection in children with type 1 diabetes. Alemzadeh R; Parton EA; Holzum MK Diabetes Technol Ther; 2009 Aug; 11(8):481-6. PubMed ID: 19698060 [TBL] [Abstract][Full Text] [Related]
55. Survey on the use of insulin pumps in Italy: comparison between pediatric and adult age groups (IMITA study). Bonfanti R; Lepore G; Bozzetto L; Corsi A; Di Blasi V; Girelli A; Grassi G; Iafusco D; Rabbone I; Schiaffini R; Laviola L; Bruttomesso D; Acta Diabetol; 2016 Jun; 53(3):403-12. PubMed ID: 26429560 [TBL] [Abstract][Full Text] [Related]
56. Ultrastructural abnormalities of the liver in total lipodystrophy. Klar A; Livni N; Gross-Kieselstein E; Navon P; Shahin A; Branski D Arch Pathol Lab Med; 1987 Feb; 111(2):197-9. PubMed ID: 3813836 [TBL] [Abstract][Full Text] [Related]